Podcasts about Cardiology

Plant-based diets lower COVID severity, cut inflammation, and help reverse environmental and health damage—especially in high-risk communities. #PandemicPrevention #ClimateHealth #FoodJustice

DAPT back in the news, a practice-changing trial in VTE therapy, new knowledge in sudden cardiac death, heart failure definitions updated, and a dumb decision by NICE in the UK are the topics discussed by John Mandrola, MD, in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Antiplatelet Therapy After Stenting DAPT-MVD Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2517588 HOST-EXAM Trial at 2 years https://pubmed.ncbi.nlm.nih.gov/34010616/ HOST-EXAM Trial at 10 years 10.1016/S0140-6736(26)00422-8 External Link Nick Kurzen on X https://x.com/ncurzen/status/2077676739463922151 II Aspirin Proves Its Mettle After Hip and Knee Replacement EPCAT III Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2603649 CRISTAL Trial https://jamanetwork.com/journals/jama/fullarticle/2795528 III New (and old) Knowledge in Sudden Cardiac Death Sudden Cardiac Death and its Relation to Cardiac Disease at Autopsy https://doi.org/10.1016/j.jacc.2026.01.029 Sudden Cardiac Death Due to MI With Obstructive and Nonobstructive Coronary Arteries https://doi.org/10.1016/j.jacc.2026.01.030 Frequency of Sudden Cardiac Death and Profiles of Risk https://www.ajconline.org/article/S0002-9149(97)00477-3/fulltext IV Heart Failure Diagnosis AHA/ACC/ESC/WHF Expert Consensus Document http://jacc.org/doi/10.1016/j.jacc.2026.05.036 V NICE Makes a Dumb Decision NICE Recommends New Nonsteroidal MRA for Heart Failure https://www.medscape.com/viewarticle/nice-recommends-new-nonsteroidal-mra-heart-failure-2026a1000nzv You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Send us Fan MailSend us Fan MailIn this enlightening episode of Living the Dream with Curveball, we sit down with Dr. Jeffrey L. Boone, a leading cardiologist and author dedicated to revolutionizing heart health. With over 30 years of experience, Dr. Boone has focused his career not just on treating heart disease but on preventing it, emphasizing the critical role that stress plays in cardiovascular health. He shares his remarkable journey from western Kansas to consulting for elite organizations like the NFL and MLB, and discusses his upcoming book, *A World Without Heart Attacks*, which aims to inspire a new approach to heart health.Dr. Boone elaborates on the importance of early detection and prevention, advocating for a shift in how we measure heart disease, moving beyond traditional risk factors to more proactive imaging techniques. He passionately argues that heart disease is often a silent killer, urging listeners to take charge of their health long before symptoms arise.Throughout the episode, Dr. Boone provides valuable insights into:- The significance of lifestyle changes and early intervention in preventing heart disease- The impact of stress on cardiovascular health and how to manage it effectively- Innovative imaging techniques that can detect heart disease before it becomes critical- The connection between heart health and brain health, and the potential to prevent dementia- His vision for making heart disease prevention accessible to everyone, not just elite athletesJoin us for a thought-provoking conversation that challenges conventional wisdom and encourages listeners to take proactive steps towards a healthier future. For more information on Dr. Boone and his work, visit booneheart.comSupport the show

Recorded at EHRA 2026, this episode of The Lead features host Michael S. Lloyd, MD, FHRS, in conversation with Tina Baykaner, MD, MPH, and Kenneth Ellenbogen, MD, FHRS, about the journal article, Real-time smartphone alerts during atrial fibrillation episodes with implantable cardiac monitors and wearable devices: SMART-ALERT study. Together, they discuss the study findings and explore the use of real-time smartphone alerts in conjunction with implantable cardiac monitors and wearable devices during atrial fibrillation episodes. Learning Objectives Review the design and key findings of the SMART-ALERT study evaluating real-time smartphone alerts during atrial fibrillation episodes. Discuss the use of implantable cardiac monitors and wearable devices for real-time detection and notification of atrial fibrillation episodes. Explore the potential clinical implications of integrating smartphone alerts with cardiac monitoring technologies.   Host: Michael S. Lloyd, MD, FHRS   Guests: Tina Baykaner, MD, MPH Kenneth A. Ellenbogen, MD, FHRS   Disclosures: M. Lloyd ·      Honoraria/Speaking/Consulting Fee: Medtronic, Boston Scientific, Other   T. Baykaner ·      Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific ·      Research: NIH, Boston Scientific   K. Ellenbogen ·      Honoraria/Speaking/Consulting Fee: American College of Cardiology, Heart Rhythm Society, Boston Scientific, Medtronic, Inc., Abbott ·      Royalty Income: Wiley-Blackwell, Elsevier

As one of the first integrative cardiologists in the country, Dr. Julius Torelli integrates the non-physical dimensions of health into patient care, emphasizing personal responsibility and a mind-body approach to well-being. Dr. Torelli tells us that the heart holds secrets that no stethoscope can detect and explores the emotional trauma that can cause cardiovascular disease and heart issues. He discusses ways to practice authentic gratitude to heal our emotional trauma and heart. 

Choléra, hépatite A, la fièvre typhoïde, poliomyélite... la contamination et le manque d'assainissement de l'eau peuvent être à l'origine de nombreuses maladies. Or, selon l'OMS, en 2022, au moins 1,7 milliard de personnes dans le monde utilisaient une source d'eau potable contaminée par des matières fécales. Quelles sont les maladies liées à l'eau ? Comment les traite-t-on ? Comment les prévenir ?   ​​​On parle souvent d'inégalités en termes d'accès à la santé dans cette émission : il y a évidemment la question des soins, du plateau technique, du financement des traitements. Mais en amont, il y a aussi les questions les plus simples d'hygiène et de prévention des infections : l'accès à l'eau potable et à l'assainissement. Une eau propre et des conditions d'hygiène satisfaisantes, ce sont certainement les bases, la toute première assurance santé avec une nourriture en quantité suffisante ! 2 milliards de personnes privées d'eau potable  Aujourd'hui, d'après l'OMS et l'Unicef, une personne sur quatre n'a pas un accès sécurisé à l'eau potable dans le monde. Alors si le lavage des mains et la propreté constituent des préoccupations personnelles et familiales, encore faut-il avoir à disposition une eau saine, des installations sanitaires convenables, au sens où elles évitent les contaminations, au cours des gestes les plus simples du quotidien : boire, se nourrir, faire ses besoins… Les maladies du péril fécal  L'eau insalubre ou l'absence d'assainissement font courir aux populations de multiples risques d'infections : choléra, hépatite A et E, fièvre typhoïde, poliomyélite, diarrhées bactériennes, amibiase... D'où l'importance d'identifier les moyens de prévenir ces maladies, pour protéger les enfants – les plus vulnérables – des infections associées au péril fécal. Avec : Pr Olivier Bouchaud, responsable du Service des Maladies Infectieuses et Tropicales, au CHU Avicenne à Bobigny, en région parisienne, président de l'Association d'Accueil aux Médecins et Personnels de Santé Réfugiés en France  Faustin Ekah Ekwele, spécialiste eau, assainissement et environnement à l'Unicef Tchad. ► Une étude publiée dans la revue The journal of American College of Cardiology démontre, chiffres à l'appui, la sous-représentation de l'Afrique dans les essais cliniques. « Un continent ignoré » : moins de 4% des essais sont menés en Afrique, pour une population qui représente près de 25% de l'humanité. Nous donnons la parole au Dr Bamba Gaye, co-auteur de l'étude, médecin chercheur, directeur exécutif de l'Alliance pour la recherche médicale en Afrique et professeur d'informatique biomédicale à la faculté de médecine d'Emory, à Atlanta. Programmation musicale :  ► Miriam Makeba – Meet me at the river ► Anitta – Pinterest. (Rediffusion) 

There's a common scene in old western movies where a weary traveler comes into town, ties up his horse in front of the tavern, and steps to the bar. The bartender always asks, “What'll you have?” If you ask that question of teenagers looking to quench their thirst with something other than water in today's world, the number one beverage of choice is energy drinks. Researchers at Piper Sandler say that thirty nine percent of respondents choose energy drinks over coffee, which is number one for thirty one percent, and soda, which is number one for thirty percent. Yes, our kids love their caffeinated beverages. But since we are called by God to steward our kids' physical well-being, we should be aware of what one Texas cardiologist, Dr. Ravi Ashwarth, is saying. He's seeing more kids who use these drinks coming in with heart palpitations, anxiety, chest pains, and shortness of breath. He gives us this directive: “energy should not come from the can. It should come from health.”

Choléra, hépatite A, la fièvre typhoïde, poliomyélite... la contamination et le manque d'assainissement de l'eau peuvent être à l'origine de nombreuses maladies. Or, selon l'OMS, en 2022, au moins 1,7 milliard de personnes dans le monde utilisaient une source d'eau potable contaminée par des matières fécales. Quelles sont les maladies liées à l'eau ? Comment les traite-t-on ? Comment les prévenir ?   ​​​On parle souvent d'inégalités en termes d'accès à la santé dans cette émission : il y a évidemment la question des soins, du plateau technique, du financement des traitements. Mais en amont, il y a aussi les questions les plus simples d'hygiène et de prévention des infections : l'accès à l'eau potable et à l'assainissement. Une eau propre et des conditions d'hygiène satisfaisantes, ce sont certainement les bases, la toute première assurance santé avec une nourriture en quantité suffisante ! 2 milliards de personnes privées d'eau potable  Aujourd'hui, d'après l'OMS et l'Unicef, une personne sur quatre n'a pas un accès sécurisé à l'eau potable dans le monde. Alors si le lavage des mains et la propreté constituent des préoccupations personnelles et familiales, encore faut-il avoir à disposition une eau saine, des installations sanitaires convenables, au sens où elles évitent les contaminations, au cours des gestes les plus simples du quotidien : boire, se nourrir, faire ses besoins… Les maladies du péril fécal  L'eau insalubre ou l'absence d'assainissement font courir aux populations de multiples risques d'infections : choléra, hépatite A et E, fièvre typhoïde, poliomyélite, diarrhées bactériennes, amibiase... D'où l'importance d'identifier les moyens de prévenir ces maladies, pour protéger les enfants – les plus vulnérables – des infections associées au péril fécal. Avec : Pr Olivier Bouchaud, responsable du Service des Maladies Infectieuses et Tropicales, au CHU Avicenne à Bobigny, en région parisienne, président de l'Association d'Accueil aux Médecins et Personnels de Santé Réfugiés en France  Faustin Ekah Ekwele, spécialiste eau, assainissement et environnement à l'Unicef Tchad. ► Une étude publiée dans la revue The journal of American College of Cardiology démontre, chiffres à l'appui, la sous-représentation de l'Afrique dans les essais cliniques. « Un continent ignoré » : moins de 4% des essais sont menés en Afrique, pour une population qui représente près de 25% de l'humanité. Nous donnons la parole au Dr Bamba Gaye, co-auteur de l'étude, médecin chercheur, directeur exécutif de l'Alliance pour la recherche médicale en Afrique et professeur d'informatique biomédicale à la faculté de médecine d'Emory, à Atlanta. Programmation musicale :  ► Miriam Makeba – Meet me at the river ► Anitta – Pinterest. (Rediffusion) 

CME credits: 0.25 Valid until: 14-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/no-patient-with-ckd-left-behind-new-horizons-in-patients-with-ckd-regardless-of-diabetes-status/49260/ A growing body of evidence presented at ERA 2026 is reshaping the conversation around chronic kidney disease management, regardless of diabetes status. In this expert interview, Dr. Katherine Tuttle and Dr. Brendon Neuen examine emerging data on nonsteroidal mineralocorticoid receptor antagonists and discuss how recent findings may expand treatment considerations for patients with chronic kidney disease (CKD), including those without diabetes. Through expert analysis of key studies and a patient perspective, the faculty explore the evolving cardiorenal landscape, practical implications for clinical practice, and opportunities to address persistent unmet needs across the CKD spectrum.=

From Patient Access to AI: Solving Cardiology's Biggest Operational Challenges Host Jenna Hagan, vice president of revenue cycle management national sales at NextGen Healthcare, chats with Nicole Knight, executive vice president of revenue cycle solutions and care transformation for MedAxiom, and Dr. Daniel Tarditi, a non-invasive clinical cardiologist, partner, and chief operating officer of The Heart House, about what it takes for cardiovascular organizations to keep pace with rising demand. They discuss why access challenges cannot be solved by asking already-stretched teams to do more, and how practices can rethink care teams, strengthen front-end revenue cycle processes, and use data to make better decisions. Nicole and Dr. Tarditi also share where AI can help when it is built into the workflow, guided by strong governance, and tied to problems that matter for patients, providers, and staff. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Dr. Ami Bhatt, Chief Innovation Officer at the American College of Cardiology and FDA Digital Health Advisory Committee chair on the rise of telemedicine and AI in healthcare. The Harvard and Yale trained cardiologist explains how and why to build the frameworks which determine how AI and digital health tools reach patients safely, equitably and at scale. Leadership, governance, and infrastructure are essential, she argues, for AI to improve patient outcomes, and to meet the challenges of scaling innovation, the shift towards hybrid, continuous and data-informed care. Patient agency, education and responsible AI adoption, she says, is vital in addressing unmet healthcare needs effectively.Follow Dr. Bhatt on LinkedIn and X, and visit dramibhatt.com for more on AI governance and the future of care delivery.• LinkedIn: linkedin.com/in/dramibhatt• X: @AmiBhattMD• Website: dramibhatt.com

Listener feedback on ICE vs TEE in AF ablation, fractional flow reserve without a wire or catheter, more bad news for ticagrelor, the POLY-HF trial, and oxygen targets after cardiac arrest are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Oct 10, 2025 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1002990 ICE vs TEE in Atrial Fibrillation Ablation https://jamanetwork.com/journals/jamacardiology/fullarticle/2839370 II FFR Without the Wire – Angiography-Derived FFR to Guide PCI ALL-RISE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600949 FAST III Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2601841 FAVOR III Trial 10.1016/S0140-6736(24)02175-5 External Link FAME 2 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1205361   Venk Murthy on X https://x.com/venkmurthy/status/2074849421452329456?s=20 III More Bad News for Ticagrelor Jul 11, 2025 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1002704 Prasugel, Ticagrelor, or Clopidogrel After PCI https://jamanetwork.com/journals/jamacardiology/fullarticle/2849614 IV The Polypill in Heart Failure POLY-HF trial https://www.nature.com/articles/s41591-026-04504-5 V Oxygen Targets After Cardiac Arrest LOGICAL Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2513814 ICU-ROX Trial https://link.springer.com/article/10.1007/s00134-020-06196-y Secondary Analysis of the PILOT Trial https://journal.chestnet.org/article/S0012-3692(25)00553-7/fulltext Oxygen Targets in Comatose Survivors of Cardiac Arrest https://www.nejm.org/doi/10.1056/NEJMoa2208686 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

On today's Good Day Health Show - ON DEMAND…Host Doug Stephan and Dr. Ken Kronhaus of Lake Cardiology (352-735-1400) cover a number of topics affecting our health. First up, Doug and Dr. Ken discuss the latest developments in medicine, technology, and preventive healthcare. The conversation explores how artificial intelligence is transforming medical diagnosis and disease prevention, allowing healthcare providers to identify health risks earlier and deliver more personalized patient care. Dr. Ken also examines advances in cardiovascular risk assessment, highlighting new tools and strategies that can help prevent heart disease before symptoms develop. The episode takes a closer look at the relationship between vaccinations and heart health, along with emerging research on neurogenesis and the brain's ability to adapt and form new neural connections throughout life. Dr. Ken discusses the importance of maintaining brain health as we age, including the benefits of treating hearing loss with hearing aids to support communication, cognitive function, and social engagement. Listeners will also hear updates on weight-loss strategies, including both prescription medications and natural supplement options, as well as a discussion of statins and alternative cholesterol-lowering therapies for cardiovascular protection.Rounding out the episode, Dr. Ken provides an update on current COVID-19 variants and vaccination strategies while emphasizing the importance of individualized healthcare decisions. Throughout the conversation, he highlights the everyday lifestyle choices—including nutrition, exercise, sleep, and social connection—that play a critical role in protecting brain health, reducing disease risk, and promoting healthy aging. Together, these topics offer listeners practical guidance and the latest medical insights for improving long-term health and wellness. For more on Good Day Health…Website: GoodDayHealthShow.comSocial Media: @GoodDayNetworks

Did you know doctors are paid systematically less for procedures on female anatomy? (For example, 45% more to biopsy a penis than a vagina). This shocking reality, highlighted by creator René Jay @bornwithadarktan and Dr. Kemi Doll's book A Terrible Strength, is a baked-in structural issue.In this episode of Our Womanity, host Dr. Rachel Pope sits down with urogynecologist Dr. Jocelyn Fitzgerald—the lead researcher behind the landmark study "Price and Prejudice"—to dismantle the financial architecture failing female patients and their specialists.Dr. Jocelyn Fitzgerald, MD is a board-certified urogynecologist and reconstructive pelvic surgeon at UPMC Magee-Womens Hospital in Pittsburgh, and an assistant professor at the University of Pittsburgh. Her clinical work and research span chronic pelvic pain, female sexual dysfunction, pelvic floor disorders, and genitourinary syndrome of menopause. She is a prominent advocate for equity in women's healthcare, famously publishing research detailing the surgical reimbursement inequities embedded within female anatomy billing.Key Conversation Highlights: The RVU Trap: How the Relative Value Unit (RVU) billing system systematically devalues the female body, gynecologic surgery, and non-surgical menopause visits. "Moms of Medicine" Dilemma: Why society expects OBGYNs to constantly absorb uncompensated emotional labor and primary care duties, diluting their specialized surgical value. The Workforce Crisis: Why post-op "ghost towns" and devalued billing are driving a massive OBGYN shortage, with only six states projected to have adequate care by 2040. Beyond "Lady Stuff": Why menopause is a systemic transition overlapping with cardiology, rheumatology, and neurology, demanding interdisciplinary research. The Allderdice Connection: A fun look back at Rachel and Jocelyn's shared feminist upbringing at Taylor Allderdice High School in Squirrel Hill, Pittsburgh."In medicine, if we don't study it and we don't name it, it's not there. It's just treated as 'lady stuff.'" — Dr. Jocelyn FitzgeraldConnect & Listen:Subscribe to Our Womanity on Apple Podcasts or Spotify, and follow Dr. Rachel Pope on Instagram: @DrRachelPope for daily midlife wellness tips!The Study: Price and Prejudice: Reimbursement of Surgical Care on Male Versus Female Anatomies by Madeline Penn, Donessa Colley, Pratistha Koirala, Dr. Louise King, and Dr. Jocelyn Fitzgerald.

We're delighted today to sit down with MDVIP Chief Medical Officer, Dr. Jeffrey Lin to talk about so building a sustainable practice, finding joy in the practice of medicine, and what's happening what the next chapter of Primary Care looks like. Dr. Jeffrey Lin is a board-certified cardiologist, internist, and the newly appointed Chief Medical Officer of MDVIP, the nation's leading network supporting physicians in personalized, preventive, and relationship-driven primary care. A Harvard Medical School graduate and Yale summa cum laude, Dr. Lin completed advanced fellowship training at Massachusetts General Hospital and Columbia University before building a distinguished career that spans academic medicine, elite sports cardiology as a consultant to the NFL Players Association, and executive leadership at Devoted Health, where he was the company's first physician hire and helped build a patient-centered care model serving over 400,000 members across 29 states. He joins MDVIP at a pivotal moment in the organization's growth, bringing with him a career-long conviction that prevention is a long game, that physician joy is inseparable from patient outcomes, and that the future of primary care depends on giving doctors the time and the tools to actually know their patients. --- MDVIP Appoints Jeffrey Lin, MD, FACC, as Chief Medical Officer     BOCA RATON, Fla. – April 22, 2026 – MDVIP, the national leader in supporting physicians to provide personalized, preventive, and primary care, today announced the appointment of Dr. Jeffrey Lin as Chief Medical Officer. A board-certified cardiologist and accomplished healthcare executive, Dr. Lin will lead MDVIP's clinical strategy and delivery as the company continues to expand its preventive and relationship-driven primary care model nationwide. Dr. Lin will also collaborate with the network's Medical Advisory Board on MDVIP's current and future offerings. The appointment reflects MDVIP's investment in physician leadership that deeply understands both the patient and provider experience, reinforcing the company's commitment to long-term health outcomes, proactive prevention, and a care model that gives doctors the time and tools to deliver truly personalized care. A cardiologist and internist by training, Dr. Lin has a longstanding commitment to prevention and optimizing health through data-driven, lifestyle-oriented approaches. He joins MDVIP from Devoted Health, where he served as National Medical Director and was the company's first physician hire, responsible for building its clinical care platform from the ground up. Since 2019, he helped lead the development and scaling of a comprehensive, patient-centered care model integrating preventive care, chronic disease management, and longitudinal wellness for primary care patients across the country, growing the clinical team to serve over 400,000 members across 29 states. As Chief Medical Officer, Dr. Lin will work closely with affiliated physicians and the MDVIP team to enhance the MDVIP experience for patients and providers alike. His priorities include strengthening MDVIP's preventive and wellness programs, supporting physicians transitioning into more manageable practice sizes, and expanding the MDVIP model to new physician segments and patient populations across different life stages. "MDVIP was built on the belief that primary care should be proactive, personal and sustainable for physicians," said Larry Kutscher, CEO and Board Chairman of MDVIP. "Dr. Lin has devoted his career to those same principles, designing care models that prioritize prevention, meaningful time with patients and better long-term health. He will be a powerful advocate for our physician community and a key partner in shaping the future of MDVIP." Dr. Lin's passion for MDVIP's mission is rooted in his early years in practice, when he saw firsthand how fragmented, specialist-heavy care consumed patients' lives and made it difficult to focus on prevention and long-term health. "As a cardiologist, I've always viewed health as a long game," said Dr. Jeffrey Lin, Chief Medical Officer of MDVIP. "The choices we make in our 40s and 60s shape the next 30 years of our lives. MDVIP has spent more than 25 years building a model that gives physicians the time and tools to focus on prevention and real relationships with patients. I'm excited to help bring that kind of care to more doctors and patients across the country." Dr. Lin also emphasized the importance of elevating the physician experience. "You can't deliver great long-term outcomes if the people providing care are burnt out," he added. "I'm looking forward to partnering with our affiliated clinicians to bring more joy back into their practice and help patients live longer, healthier lives." With the appointment of Dr. Lin, MDVIP is beginning a new chapter in its growth story, doubling down on personalized, relationship-centered care and expanding its influence among patients and physicians nationwide. About Dr. Jeffrey Lin Dr. Jeffrey Lin is a board-certified cardiologist, internist, and an accomplished physician executive dedicated to advancing personalized, preventive, and relationship-driven care. He previously served as National Medical Director at Devoted Health, a tech-enabled Medicare Advantage organization, where he's helped lead the development and scaling of a comprehensive, patient-centered care model nationwide since 2019. A cardiologist by training, Dr. Lin has a longstanding commitment to prevention and optimizing cardiovascular health through data-driven, lifestyle-oriented approaches. Earlier in his career, he served as Assistant Professor of Medicine at Mount Sinai Medical Center in Miami Beach and Co-Director of Cardiac Rehabilitation, where he built a thriving ambulatory cardiology practice and developed programs that enabled patients to achieve meaningful, sustained improvements in heart health. Dr. Lin's experience also includes caring for elite and professional athletes as a cardiology consultant to the National Football League Players Association, as well as leading clinical research on cardiovascular performance and endurance. His work has been published in leading medical journals, including the Journal of the American College of Cardiology and Circulation. He is also a Fellow of the American College of Cardiology. Dr. Lin earned his medical degree from Harvard Medical School and graduated summa cum laude from Yale University. He completed his residency in internal medicine at Columbia University Medical Center, followed by advanced fellowship training in cardiovascular medicine, sports cardiology, and cardiac imaging at Massachusetts General Hospital and Columbia University.

Ep. #812 | One of the most critical habits for improving erections, and a simple mental approach to help you get it done.Inquiries: contact@holisticalpha.comStudiesKhera M, Bhattacharyya S, Miller LE. (2023). Effect of aerobic exercise on erectile function: Systematic review and meta-analysis of randomized controlled trials. Journal of Sexual Medicine.https://academic.oup.com/jsm/article/20/12/1369/7301709https://pubmed.ncbi.nlm.nih.gov/37814532/Gerbild H, Larsen CM, Graugaard C, Areskoug Josefsson K. (2018). Physical activity to improve erectile function: A systematic review of intervention studies. Sexual Medicine.https://pmc.ncbi.nlm.nih.gov/articles/PMC5960035/Silva AB, Sousa N, Azevedo LF, et al. (2017). Physical activity and exercise for erectile dysfunction: Systematic review and meta-analysis. British Journal of Sports Medicine.https://pubmed.ncbi.nlm.nih.gov/27707739/Esposito K, Giugliano F, Di Palo C, et al. (2004). Effect of lifestyle changes on erectile dysfunction in obese men: A randomized controlled trial. JAMA.https://jamanetwork.com/journals/jama/fullarticle/198993Begot I, Peixoto TC, Gonzaga LR, et al. (2015). A home-based walking program improves erectile dysfunction in men with an acute myocardial infarction. American Journal of Cardiology.https://pubmed.ncbi.nlm.nih.gov/25727080/Maio G, Saraeb S, Marchiori A. (2010). Physical activity combined with PDE5 inhibitor therapy improves erectile function more than medication alone.https://pubmed.ncbi.nlm.nih.gov/20367777/Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. (2006). A prospective study of risk factors for erectile dysfunction. Journal of Urology.https://pubmed.ncbi.nlm.nih.gov/16753404/Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. (2000). Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. Journal of Urology.https://pubmed.ncbi.nlm.nih.gov/10731462/Dorey G, Speakman M, Feneley R, Swinkels A, Dunn C. (2004). Randomized controlled trial of pelvic floor muscle exercises and biofeedback for erectile dysfunction. BJU International.https://pubmed.ncbi.nlm.nih.gov/15527607/Chen Z, et al. (2024). Effect of different physical activities on erectile dysfunction: A systematic review and network meta-analysis. Andrology.https://onlinelibrary.wiley.com/doi/full/10.1111/andr.13682

Send us Fan MailHeart valve disease affects millions of people, yet treatment isn't one-size-fits-all. When surgery becomes necessary, doctors may recommend repairing the existing valve or replacing it entirely. In today's episode, Dr. Richard Kettelkamp, medical director for St. Luke's Heart Care Services, returns to the podcast to break down each option, discuss how doctors decide which approach is best, and what it means for patients and their quality of life. To learn more, visit unitypoint.org/cr-heart. If you have a topic you'd like Dr. Arnold to discuss with a guest on the podcast, shoot us an email at stlukescr@unitypoint.org.

Understanding how values and communication styles differ across cultures is key to succeeding internationally. That’s why training in cross-cultural communication has become commonplace in the international business world. In this session, we’ll look at 6 dimensions of cross-cultural communication and their application to medical scenarios.

If you're scheduled for angioplasty this episode walks through the patient experience from pre-procedure preparation to same-day discharge and follow-up care. Dr. Ahmad A. Hadid explains sedation during cardiac catheterization, stent placement, common recovery steps, signs to watch for after discharge, and how same-day angioplasty improves convenience and family support for patients with coronary artery disease. Searchable topics included are angioplasty, recovery after angioplasty, stent, cardiac catheterization, same-day procedure, and follow-up care. For more details visit montefioreslc.org and subscribe to DocTalk.

Refined and processed vegan foods can raise heart disease risk just like meat. Whole plants always outperform ultra-processed alternatives. #VeganJunkFood #ProcessedFoods #HeartSafe

CME credits: 1.00 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/gaps-global-implementation-lipid-guidelines/54672/ A new modular CME-accredited program designed to support clinicians in translating evolving lipid guidelines into everyday practice. Delivered as a 60-minute webcast, divided into chapters for convenience, it integrates U.S. and international perspectives and focuses on equitable cardiovascular care. The course highlights women-specific cardiovascular risk modifiers, including reproductive and hormonal factors that are often under-recognized in risk assessment. It also emphasizes practical, multidisciplinary approaches to improving lipid management outcomes across diverse health systems. =

Listener feedback on valvular heart disease, statins and frailty, left atrial posterior wall ablation fails again, interpreting medical tests and AI ECG reading are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback PREVUE-VALVE Study https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5137 II Statins and Frailty Statin Initiation Tied to Lower Frailty Risk in Older Adults https://www.medscape.com/viewarticle/statin-initiation-tied-lower-frailty-risk-older-adults-2026a1000lec Statins and Survival Free of Incident Frailty  https://doi.org/10.1093/eurheartj/ehag451 III LA Posterior Wall Isolation Fails Again CORNERSTONE Trial https://doi.org/10.1093/eurheartj/ehag486 CAPLA Trial https://jamanetwork.com/journals/jama/fullarticle/2800186 IV Does the Display of Test Results Improve Clinical Decisions? Interval Likelihood Ratios for Clinical Decsion-Making https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500249 Making Sense of Health Statistics https://journals.sagepub.com/doi/full/10.1111/j.1539-6053.2008.00033.x V AI and the ECG and Saving Doctors Case Report — AI-Enhanced Diagnostics https://www.nature.com/articles/s41591-026-04454-y The New York Times article https://www.nytimes.com/2026/06/22/health/artificial-intelligence-heart-damage.html You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we review a recent meta-analysis of studies assessing efficacy of adenosine in children to terminate SVT. Does the PALS recommendation of 100 mcg/kg as a starting dose for SVT management make scientific sense given what we know about the efficacy rates of this dose? Why might inadequate doses be potentially dangerous for children with acute SVT? Is there adequate data to consider changes to the recommended starting dose in this situation? Dose adenosine work well for all forms of tachycardia involving the AV node? Pediatric emergency physician and family medicine physician, Dr. Lais dos Santos of Mossoro', Brazil shares the results of a large scale meta-analysis that she performed and offers some answers to these and other questions. DOI: 10.1007/s00246-026-04281-5

The newest AHA and ACC guidelines for treating dyslipidemia are here — and according to Dr. Kim Williams, they mark a powerful shift toward prevention, earlier testing, and whole-food, plant-based nutrition as the foundation of cardiovascular care.Rip welcomes back Dr. Kim Williams, past president of the American College of Cardiology, for a practical and deeply encouraging breakdown of what these updated cholesterol guidelines mean for everyday people.Dr. Williams explains why cardiovascular risk is no longer just about one cholesterol number. Instead, clinicians are being encouraged to look at the whole picture: LDL cholesterol, ApoB, Lp(a), inflammation, blood pressure, blood sugar, kidney function, family history, lifestyle, and coronary artery calcium when appropriate.The most exciting part for the PlantStrong community? Lifestyle optimization is now treated as the clinical foundation — and Dr. Williams is clear about what that means: a whole-food, plant-based diet built around beans, grains, nuts, seeds, fruits, vegetables, and mushrooms, along with exercise, sleep, mindfulness, strong social connections, and avoidance of tobacco, alcohol, and other harmful substances.This conversation also tackles statins, PCSK9 inhibitors, Lp(a), coronary calcium scoring, and the new philosophy of treating risk lower, earlier, and longer — always with food first, and medication when needed.Key TakeawaysThe new cholesterol guidelines emphasize lifestyle first, not lifestyle as an afterthought.Dr. Williams says a whole-food, plant-based diet should be built around beans, grains, nuts, seeds, fruits, vegetables, and mushrooms.LDL cholesterol is still important, but it is no longer the only number that matters.ApoB may give a clearer picture of risk in some people, especially those with diabetes, high triglycerides, or central obesity.Lp(a) is largely genetic and should be measured at least once in adulthood; the 2026 guideline includes updated recommendations for elevated Lp(a).Coronary artery calcium scoring can help personalize risk and guide LDL targets.Dr. Williams emphasizes that the goal is not “plants versus statins.” It is whole plant foods first, medications when needed.The overall prevention philosophy is: lower, earlier, longer.Watch the Episode on YouTube: https://youtu.be/6cD8tGpsAggLearn More About our 2026 Live PLANTSTRONG Events: https://plantstrongevents.com/ Let Us Help Your PLANTSTRONG JourneyLearn More About Our Corporate Wellness Program: https://liveplantstrong.com/corporate-wellness/ COMPLEMENT: Use code PLANTSTRONG for 30% off at https://lovecomplement.com/pages/plantstrong-special-offer Follow PLANTSTRONG and Rip Esselstynhttps://plantstrong.com/ https://www.facebook.com/GoPlantstrong https://www.instagram.com/goplantstrong/https://www.instagram.com/ripesselstyn/ Follow the PLANTSTRONG Podcast and Give the Show a 5-star RatingApple PodcastsSpotify

This episode is part of our comprehensive Decipher the Guidelines Series covering the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.  The following question refers to Section 5.2.1 of the 2025 ACS Guidelines. The question is asked by Thomas Jefferson medical student and CardioNerds Academy Intern Dr. Grace Qiu, answered first by Henry Ford Interventional cardiology fellow and member of the CardioNerds Interventional Cardiology Council Dr. Li Pang, and then by expert faculty Dr. Michelle O'Donoghue. Dr. O'Donoghue is a cardiologist, senior investigator with the TIMI Study Group, and Associate Professor of Medicine at Harvard Medical School who holds the McGillycuddy-Logue Endowed Chair in Cardiology at Brigham and Women's Hospital. She was the Vice Chair of the Writing Committee for the 2025 ACS Guidelines. Question #2 A 63-year-old woman presented to the emergency room for chest pain. She described having exertional chest pain for the past two months and had an episode of severe pain after dinner 3 days ago. She went to bed and slept it off.  She told her children today at a family gathering, and was immediately brought to the ED by her daughter. She has a history of hypertension and hyperlipidemia. She was asymptomatic and normotensive in the ED. Labs show a down-trending troponin and an elevated NT-proBNP but are otherwise unremarkable. Her ECG showed Q waves with ST elevation in V2-V4. She was treated with aspirin and heparin drip, and taken to the cath lab. Coronary angiogram showed complete proximal LAD occlusion with right-to-left collaterals, without significant residual disease elsewhere. She remains asymptomatic and is stable, both hemodynamically and electrically. What is the next best step with regard to reperfusion and anti-thrombotic management? A Proceed with primary PCI to LAD  B Medical management with aspirin and enoxaparin  C Medical management with aspirin and clopidogrel D Medical management with aspirin and ticagrelor   Answer #2 Explanation  The Correct answer is D In patients who are stable with STEMI and have a totally occluded infarct-related artery >24 hours after symptom onset and are without evidence of ongoing ischemia, acute severe HF, or life-threatening arrhythmia, PPCI should not be performed due to lack of benefit. (Class 3, LOE B-R) The benefit of PPCI begins to diminish after >12 hours from symptom onset, but there appears to be continued benefit through approximately 24 hours.  In stable asymptomatic patients with an occluded artery >48 hours after symptom onset, routine PCI has not been shown to be beneficial in the absence of ongoing ischemia. The relative utility of routine PCI for asymptomatic patients with STEMI between 24 and 48 hours from symptom onset is less rigorously tested. PCI is not recommended for an occluded infarct-related artery if the patient is asymptomatic and has a completed infarct. MACE outcomes were similar in those with an occluded infarct-related artery who underwent medical therapy versus those who underwent PCI 3 to 28 days after an MI (Occluded Artery Trial [OAT]), and results were no different at 7-year follow-up. Similar findings were noted in the DECOPI (Desobstruction Coronaire en Post-Infarctus) trial, which enrolled patients with an occluded artery and Q waves on the ECG presenting 2 to 15 days after symptom onset. However, coronary revascularization should be considered for patients with late presentations with continued signs and symptoms of ischemia, including cardiogenic shock, acute severe HF, persistent angina, and life-threatening arrhythmias.  Main Takeaway In patients who are stable with STEMI who have a totally occluded infarct-related artery >24 hours after symptom onset and are without evidence of ongoing ischemia, acute severe HF, or life-threatening arrhythmia, PPCI should not be performed due to lack of benefit. Guideline Loc. Section 5.2.1 

Chris Altchek, founder and CEO of Cadence, joins Nikhil and Jacob to discuss how AI is changing the way chronic disease gets managed at scale. Cadence treats 100,000 patients a day across major health systems and has published some of the largest cost and outcomes studies in the space, including a nearly 17,000-patient analysis in Mayo Clinic Proceedings and a 24,000-patient study in the Journal of the American College of Cardiology. The conversation covers the three phases remote patient monitoring has gone through since before COVID, why hospital-at-home has struggled to scale despite strong clinical outcomes, and how AI voice agents cut Cadence's average alert response time from 1.8 hours to 3.5 minutes. Chris also explains Cadence's "proactive titration agent" for adjusting medications in real time, an unexpected discovery that their monitoring system catches early signs of sepsis, and why he believes digital health companies have a responsibility to engage with new CMS payment models like ACCESS, even when the economics aren't ideal on day one. They close on how Cadence is rethinking hiring and internal workflows as AI changes what the job requires. (0:00) Intro (1:22) Remote Monitoring Three Phases (3:44) Why Hospital at Home Stalled (6:06) Cadence Vision and Scale (8:50) GenAI Boosts the Product (13:45) Where AI Still Breaks (18:30) Building Proactive Workflows (22:50) Outcomes and Surprising Savings (25:07) Access Program and Payment Model (30:10) Engaging Seniors at Scale (34:42) Wearables FDA and Device Costs (37:59) Running a Company with AI (41:15) Quickfire Out-Of-Pocket: https://www.outofpocket.health/

CardioNerds (Amit and Dan), Billy Joe Mullinax, and Saahil Jumkhawala discuss the long term management of pulmonary embolism with Dr. Soophia Naydenov.  The episode focuses on the approach to patients who struggle with persistent symptoms like dyspnea and fatigue even after completing the acute phase of anticoagulation. This spectrum of disease, ranging from mild post-PE impairment to chronic thromboembolic pulmonary hypertension (CTEPH), requires a structured follow-up. The discussion covers the critical importance of identifying CTEPH early, the necessary timelines for follow-up, and the appropriate objective screening tools and invasive testing to guide patient care toward full functional recovery. Audio editing by CardioNerds academy intern, Grace Qiu. Dr. Dinu Balanescu and Dr. Billy-Joe Mullinax are Co-chairs for the CardioNerds PE Series, developed in collaboration with the PERT Consortium.   Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Pulmonary Embolism PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Acronyms PE: Pulmonary Embolism PERT: Pulmonary Embolism Response Team CTEPH: Chronic Thromboembolic Pulmonary Hypertension QL: Quality of Life VTE: Venous Thromboembolism DASH: D-dimer, Age, Sex, History of non-provoked PE (a risk score) CPET: Cardiopulmonary Exercise Testing PFTs: Pulmonary Function Tests VQ Scan: Ventilation-Perfusion Scan DOACs: Direct Oral Anticoagulants TPA: Tissue Plasminogen Activator (Thrombolytics) ECMO: Extracorporeal Membrane Oxygenation Pearls: Post-PE “Syndrome” is a Spectrum: It is more accurately a spectrum of disease (sequelae of PE) rather than a single syndrome, ranging from mild fatigue/dyspnea to the most severe form, CTEPH. Structured Follow-up is Mandatory: All PE survivors need a structured follow-up, typically with checkpoints at 3, 6, 12, and 16–24 months, with the primary goal being to detect CTEPH, the deadliest, yet potentially curable, disease on the spectrum. Screening Should Be Objective and Practical: When screening for persistent symptoms, use objective assessment tools like the Post-VTE Functional Status (PVFS) scale or the Modified Medical Research Council (MMR-C) scale, as highly comprehensive but cumbersome tools (like the PE Quality of Life questionnaire) may not be practical for routine clinical use. Recurrence Risk Scores Aid in Anticoagulation Duration: Simple scores like the DASH score or the HERDO2 score (for women) can provide guidance when considering the continuation versus discontinuation of anticoagulation after the initial treatment phase. Invasive Testing for Persistent Symptoms: If a patient remains symptomatic at the 6-month mark despite normal non-invasive testing (chest X-ray, ECG, PFTs, six-minute walk, echo, VQ scan, CPET), consider invasive testing such as Right Heart Catheterization (RHC) at rest or with exercise, or an invasive CPET. Notes: Notes drafted by Saahil Jumkhawala. 1. The Spectrum of Post-PE Disease The term “post-PE syndrome” should be used with caution, as it refers to a spectrum of disease rather than a single entity. This spectrum includes symptoms (sequelae) that exist in a patient’s life following an incidental PE event that they did not have before. On one extreme is Chronic Thromboembolic Pulmonary Hypertension (CTEPH): The definition is clear, but it is the most deadly type, though thankfully rare (2% to 4%). It involves a residual clot and pulmonary hypertension identifiable at rest. In the middle is Chronic Thromboembolic Disease (CTED): Patients may have residual defects seen on a VQ or CT scan, but they do not have pulmonary hypertension. On the other side is a milder disease, which can include fatigue, dyspnea, or a patient’s perceived impairment, where the definitions of CTEPH and CTED are not met, but the patient remains symptomatic. 2. Structured Follow-up and Screening for Post-PE Symptoms Structured follow-up is key for all PE survivors, though the structure may vary based on available resources (PCP, Cardiology, Pulmonary, or multidisciplinary clinic). Recommended Timeline for Follow-up: Data from studies like ELOPE and FOCUS suggest checkpoints at 3, 6, 12, and up to 16 to 24 months. This timeline is designed to identify patients who may develop CTEPH. 88% of patients who develop CTEPH will be identified within about a year. A structured follow-up can reduce the delay in CTEPH diagnosis from 10–12 months to 4–6 months. Personal Practice Note: A quick 2–3 week/30-day check-in is recommended for severely ill patients (e.g., those who had TPA, profound shock, or ECMO support) to ensure medication compliance, manage symptoms, and identify red flags. Screening Tools (Objective Assessment): The first step is an inventory of patient symptoms, leaning toward objective rather than subjective assessment. Recommended Simple Tools: Modified Medical Research Council (MMR-C) for dyspnea evaluation. Post-VTE Functional Status (PVFS) scale. The Pulmonary Embolism Quality of Life (QL) questionnaire is comprehensive but long, making it tedious and better suited for research. Future Utility: Technology (AI/electronic tools) may assist in administering these questionnaires before the clinic visit, presenting the information as a “dashboard” for the provider. 3. Management of Persistent Symptoms and Further Testing Initial Non-Invasive Tests (Often done at 3 months): Echocardiogram VQ Scan Full PFTs Six-minute walk CPET Further Evaluation for Persistent Symptoms (e.g., at 6 months): If non-invasive tests (Chest X-ray, ECG, CPET) are normal but symptoms persist, more invasive testing should be considered as the patient has not returned to baseline. Repeat VQ scan or echocardiogram if symptoms have changed. Right Heart Catheterization (RHC) at rest or with exercise. Invasive CPET. PA gram (Pulmonary Angiogram) to assess vasculature. 4. Recurrence Risk and Anticoagulation Duration The decision to continue or discontinue anticoagulation depends on the patient’s risk factors, the situation of the PE (provoked or unprovoked), presence of active cancer, and patient preference. Recurrence Risk Scores: Simple scores are preferred for practicality. DASH Score. HERDO2 Score (particularly for women). The Vienna Score can be considered if the question is whether to restart anticoagulation after a disruption. Role of D-dimer in Abbreviation: While D-dimer can be used to guide the decision to restart anticoagulation after a planned pause (if D-dimer is high, resume), patient symptoms are preferable to guide management decisions like early abbreviation. 5. Prevention of Post-PE Syndrome Currently, there is no clear tool known to prevent the post-PE syndrome/spectrum of disease. Best Current Advice for Prevention/Recovery: Anticoagulation compliance. Pulmonary rehabilitation, which aids in faster recovery. General precautions, such as smoking cessation and body weight management. Future Research: Ongoing trials are investigating whether acute management strategies (e.g., using thrombolytics in intermediate-risk PE) can prevent long-term sequelae. (The PYTHO trial did not show a reduced rate of CTEPH in intermediate-risk PE patients who received thrombolytics). References: Khan, F., Tritschler, T., Kahn, S. R., & Rodger, M. A. “Venous Thromboembolism.” The Lancet, vol. 398, no. 10294, 2021, pp. 64-77. doi:10.1016/S0140-6736(20)32658-1. Kearon, C., & Kahn, S. R. “Long-Term Treatment of Venous Thromboembolism.” Blood, vol. 135, no. 5, 2020, pp. 317-325. doi:10.1182/blood.2019002364. Kahn, S. R., & de Wit, K. “Pulmonary Embolism.” The New England Journal of Medicine, vol. 387, no. 1, 2022, pp. 45-57. doi:10.1056/NEJMcp2116489. Di Nisio, M., van Es, N., & Büller, H. R. “Deep Vein Thrombosis and Pulmonary Embolism.” The Lancet, vol. 388, no. 10063, 2016, pp. 3060-3073. doi:10.1016/S0140-6736(16)30514-1. Chopard, R., Albertsen, I. E., & Piazza, G. “Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review.” JAMA, vol. 324, no. 17, 2020, pp. 1765-1776. doi:10.1001/jama.2020.17272.

More than 60% of maternal deaths occur during the postpartum period, and hypertensive disorders of pregnancy are a major, preventable driver of that statistic. For too long, the transition from labor and delivery to home has been a vulnerable blind spot—leading to high rates of avoidablereadmissions. But the landscape has shifting. In this episode, we are diving deep into why OB providers must optimize blood pressure control before and after postpartum discharge. We'll be breaking down the landmark 2025 MOPP study, which shook up our traditional targets by examining tight versus standard blood pressure control, alongside the recently released May 2026 ACC Expert ConsensusDecision Pathway.What is the actual "goal BP" for a safe postpartum discharge? When should we initiate outpatient tight control, and how do we prevent these patients from bouncing back to the ED? Grab your coffee and pull up a chair. Let's look at the evidence.20% DISCOUNT: https://strongcoffeecompany.com/discount/CHAPANOSPINOBG1.          Gibson K, Hameed A. Society for Maternal-Fetal Medicine Special Statement: Checklist forpostpartum discharge of women with hypertensive disorders. AJOG, 2020. 2.          Farahi N, Oluyadi F, Dotson AB. Hypertensive Disorders of Pregnancy. American Family Physician. 2024. 4.          Lindley KJ, Bello NA, Berlacher KL, et al. Optimization of Postpartum Care for Patients With and at Risk for Premature and Long-Term Cardiovascular Disease: 2026 ACC Expert Consensus. Journal of the American College of Cardiology. May 2026. 5.          ACOG Task Force on Hypertension in Pregnancy, 20136.          Rosenfeld EB, Sagaram D, Lee R, et al. Management of Postpartum Preeclampsia and Hypertensive Disorders (MOPP): Postpartum Tight vs Standard Blood PressureControl. JACC. Advances. 2025.

Listener feedback, more long-term data on the TAVR/SAVR question, population prevalence of valvular heart disease in the US, and a CMS proposal to expand TAVR coverage are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback ICD Trends and Outcomes: 15-Year Analysis https://doi.org/10.1093/europace/euag110 MADIT-RIT https://www.nejm.org/doi/full/10.1056/NEJMoa1211107 II More Long Term Data on TAVR vs SAVR PARTNER 2 Trial https://www.jacc.org/doi/10.1016/j.jacc.2026.03.169 10-Year Outcomes of SAPIEN 3 TAVR or SAVR in Intermediate-Risk Patients https://doi.org/10.1016/j.jacc.2026.03.170 TAVR at a Decade: Editorial https://doi.org/10.1016/j.jacc.2026.04.042 EVOLUT Trial https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063 Updated 5-year Outcomes of TAVR vs SAVR in AS https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092 NOTION Trial https://doi.org/10.1093/eurheartj/ehae043 PARTNER 3 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2509766 NOTION 2 Trial https://academic.oup.com/eurheartj/article/45/37/3804/7673297 TAVR vs SAVR Editorial : https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehag407/8708044 III The PREVUE-VALVE Study PREVUE-VALVE Study https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5137 IV CMS has Proposed New Coverage for TAVR CMS Proposal Document https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&ncaId=321 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we review a recent report of a novel form of CPVT (catecholaminergic polymorphic ventricular tachycardia) with associated neurodevelopmental delays. What is the genetic basis for these patients? What is different about the arrhyhthmias seen and how they are triggered in this variant? Should all patients with CPVT be screened for neurodevelopmental delays? Should those with neurodevelopmental delays and RYR2 variants be screened for CPVT? Associate Professor of Peditrics at Baylor College of Medicine/Texas Children's Hospital, Dr. Christina Miyake, shares her deep insights this week. doi: 10.1161/CIRCEP.124.013437

Primary stroke prevention is a critical opportunity for neurologists, with most stroke risk driven by modifiable factors such as hypertension and lifestyle behaviors. This episode highlights practical tools and strategies, including Life's Essential 8 and contemporary risk calculators, while also exploring evolving approaches to shared decision making and secondary prevention. In this episode, Katie Grouse, MD, FAAN, speaks with Mitchell S. Elkind, MD, MS, FAAN, author of the article "Stroke Prevention" in the Continuum® June 2026 Cerebrovascular Disease issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California, San Francisco in San Francisco, California. Dr. Elkind is the Chief Science Officer for Brain Health and Stroke at the American Heart Association in Dallas, Texas, and a professor of neurology and epidemiology at Columbia University in New York, New York. Additional Resources Read the article: Stroke Prevention Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Guest: @MitchElkind Full episode transcript available here Dr Grouse: Neurologists have generally been more involved in secondary stroke prevention, but primary stroke prevention is increasingly recognized as an important topic of discussion for neurologists. Today, I have the opportunity to interview Dr. Mitchell Elkind, who wrote the article on stroke prevention in the newest Continuum issue on cerebrovascular disease.  Dr Jones: This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast.  Dr Grouse: This is Dr. Katie Grouse. Today, I'm interviewing Dr. Mitchell Elkind about his article on stroke prevention. This article appears in the June 2026 Continuum issue on cerebrovascular disease. Welcome to the podcast, and please introduce yourself to the audience.  Dr Elkind: Thank you so much, Katie. So, my name is Mitch Elkind, and I'm the Chief Science Officer for Brain Health and Stroke at the American Heart Association and a stroke neurologist by background.  Dr Grouse: Well, I just want to start by saying that I really enjoyed reading this article. I think this is just a really wonderful article I recommend strongly. Such a high yield, an important topic for a lot of us who see patients who are interested in learning about their stroke risks or need help with, uh, stroke prevention after having a stroke. So, I wanted to start. What's changed in the last couple of years? You know, what are some big highlights that you really want to stress that are different from maybe the last time we reviewed this topic?  Dr Elkind: Sure. Well, there's been a lot of development in the field of secondary stroke prevention, for one thing. But even beyond that, I think we increasingly appreciate how important it is to control what we call the social drivers of health on the earlier side, primordial or primary prevention. And that has been a big advance, I'd say. And I would also say, I think it's really important for neurologists to understand some of those questions about primordial and primary prevention. You know, we tend to get involved with patients after they've had a stroke or maybe a TIA, some kind of event. But sometimes we find people who are following for, you know, non-stroke related conditions who have risk factors also. And we can really play an important role in identifying those risk factors and helping to prevent a first stroke or vascular event as well. So, I think it's real important for us to be doctors even before we're neurologists. So, you know, Katie, about ninety percent of stroke risk is modifiable, so we can do a great job as neurologists in preventing stroke. And one of the most important things that we can do is to identify and treat high blood pressure. And recently, actually, the American Heart Association, American College of Cardiology guidelines on the management of hypertension have said that treatment of high blood pressure not only prevents stroke, but it can also help to prevent cognitive decline and dementia. And this is the first time that we've had a class of recommendation one and level of evidence A, the highest level of recommendation we give for the use of blood pressure treatment to prevent dementia. And that's largely based on the results of some large trials that have come out recently showing that you can prevent dementia with blood pressure control. So that's a really exciting link, I think, between cardiovascular risk factor control and subsequent brain health. It just illustrates the role that neurologists can play in, so many conditions outside of stroke as well.  Dr Grouse: That's a really great point, and I want to get a little more into the idea of primordial stroke prevention. Can you tell us a little bit more about what that might be?  Dr Elkind: So primordial prevention refers to addressing how we can prevent risk factors from occurring in the first place, and how can we improve the environments in which people live. You know, we know that only about twenty percent of health outcomes is dependent on what happens between the patient and their doctor in the office. About eighty percent of it is due to what happens in the environments in which we live, work, pray, and play. And so that's what we mean when we refer to the social drivers of health. What is the neighborhood like where somebody lives? Do they have access to healthy food? Do they have places where they can go to exercise? Is there air pollution in the area that may affect their health? You know, one really interesting fact that's become apparent in the last few years is that air pollution is a major risk factor for stroke. Something like a sixth of all strokes can be attributed to the quality of air. And so, what are the things we can do at the broader public policy, community level to reduce the risk of risk factors like high blood pressure and diabetes even before somebody has an event that brings them to the attention of the doctor? So that's what we're thinking about with regard to primordial prevention. It's the earliest stage in prevention.  Dr Grouse: And that's really fascinating. You know, I think an area that we haven't, as neurologists, really put a lot of our time thinking about, but clearly a very important thing. I really appreciated reading your article about how you incorporated the fact that, you know, a lot of these risk factors overlap very, very closely with all the risk factors for various types of cardiovascular events. And I would imagine that the work you've done as the Chief Clinical Science Officer for the American Heart Association has informed a lot of the way you've thought about-Trying to bring all these risks together and think a little bit more holistically about the whole thing. Could you tell us a little bit more about that and the work that you've done on the American Heart Association's Life's Essential 8 score?  Dr Elkind: Sure. I can't take credit for it. It's really work that was done by others at the Heart Association, particularly a cardiologist and epidemiologist named Don Lloyd-Jones. But many other volunteers participated. Life's Essential 8 is our approach to primary stroke prevention and cardiovascular prevention more broadly. We say Life's Essential 8 because it includes four health behaviors and four health factors that people can observe to reduce their risk of cardiovascular disease. The four factors are kind of things like know your numbers, your blood pressure, your blood sugar, your body mass index, right, which is a combination of weight and height, and your cholesterol level. So, know those numbers and keep them within the recommended ranges, and talk to your doctor if they're not. And then four lifestyle behaviors. So, one of them is to eat a healthy diet, and typically that means the Mediterranean diet. It means getting regular exercise, and we recommend 150 minutes a week of moderate to vigorous physical activity. Of course, it means abstinence from smoking or other tobacco products. And the last one, the eighth one, which I was so excited about when we added this, is sleep, recommending at least seven hours of sleep a night. So, I was really excited about this because we used to talk about Life's Simple 7, and then the last iteration of our recommendations included this recommendation for adequate sleep because of the mounting evidence of the importance of sleep to cardiovascular health. But sleep is really a brain function, right? And so, it was really the first, in a way, specific brain function that was added to our recommendations. So that's Life's Essential 8. People can read about it online at heart.org and recommend it to your patients as a simple way for people to understand the best approach to reducing their risk of cardiovascular disease, including stroke.  Dr Grouse: I checked it out myself after reading the article. It's very accessible to patients. It's a great education tool. And they can, you know, see their own score and use that in their own way to, to think about what their risks are and how they can help mitigate and then rescore themselves down the line. There's also, though, on the kind of more the clinician side, the PREVENT calculator as well. Could you tell us a little bit more about how we could use that in approaching this patient population?  Dr Elkind: Yeah. So, I think of Life's Essential 8 as being a patient-focused tool that people can use. PREVENT is really more for clinicians. Anybody can look it up online and enter your data into it. There's a risk calculator online. But the basic idea behind PREVENT and other similar risk calculators is that it's a way to estimate somebody's risk of having a cardiovascular event like stroke or a heart attack or even heart failure by entering information about your health. And we used to think, we used to use something called the ASCVD, atherosclerotic cardiovascular disease risk calculator, or the Framingham score. Framingham Heart Score, for example, was another one. PREVENT is the latest version, and it has several advantages over those earlier types of risk predictors. For one thing, it predicts risk at younger ages as well. It goes down to age 30. It predicts risk over a longer duration of time, so over 30, 10 or 30 years. It eliminates the use of race as an item to put into the calculator and substitutes for that socioeconomic status, so it's not a race base, but a measure of social disadvantage. And it also includes kidney elements, kidney measures. It includes renal function, for example, that weren't included in prior measures, and it can also be used to predict heart failure, which was not part of the original calculators. Another major advantage of the PREVENT study is that it was based on real-world data from about three million patients, many, many more than the 50,000 or so that the earlier risk calculators were based on. So, it has a much more robust data set and therefore allows a bit more precision in the ability to predict future risk of events. And typically, primary care doctors would enter their patient's data, calculate a risk, and then based on the results of the risk calculator, they can make recommendations about what type of medications a person should take or what other strategies they could use to reduce their risk. And so that's the role that PREVENT plays, is really being focused more for the clinician than the patient.  Dr Grouse: Really great tool for us to be aware of. You earlier alluded to the fact that neurologists are in the situation where we sometimes are helping patients with this primary prevention. But you also make a case for why it's in the patient's best interest for us to be involved in, in these conversations when we can, when we have the opportunity. Can you tell us more about that?  Dr Elkind: Shared decision-making is really important because we know that people aren't going to lead the healthiest possible lives if they're not invested in their care. And so, a doctor telling somebody what to do if the patient doesn't want to do it is gonna have limited benefit.So we emphasize the importance of shared decision-making as much as possible. And I think that where this comes up a lot is actually in the situation of, for example, atrial fibrillation, where patients will often be put on a blood thinner. And many people are fearful of blood thinners. They worry about the risk of bleeding. Maybe they know a relative who's had a bleeding complication from a blood thinner, and so they may be disinclined to try it. And so, it's really important to have these discussions about the risks and the benefits of medication and engage the patient in thinking about this. And there are even tools and visual aids that people can look to to help explain some of these complicated concepts to patients. So, these are the kinds of things that reflect implementation science as a way to improve adherence. We know what works in a clinical trial setting often, but the challenge is translating that into the real world and getting our patients to use the medications that we believe scientifically have been shown to be of benefit. I've actually been surprised sometimes at conversations I've had with people, in some cases, healthcare professionals who resist going on blood thinners because of their fear of the complications. And I feel like the evidence is there. Why don't they believe me? And that's why it's really important to have the conversation. Even our peers and colleagues can sometimes question the evidence, and it's important for us to be aware of that.  Dr Grouse: Absolutely. I think that sounds very reasonable to me, and hopefully these tools will help us with making some of these decisions with our patients. Now, turning our attention a little bit to secondary prevention. So, you know, someone's already had a stroke or a TIA, sort of thinking about what we can do to optimize their risk factors for further strokes. You know, I think there has been some changes that have happened, I think, in the last few years that might be affecting some of the decisions we're making and some of the advice we're giving our patients. I wanted to talk a little bit about GLP-1 receptor agonist medications. Is the data there to support use of this either in secondary prevention or even in primary prevention in the case of stroke?  Dr Elkind: There is evidence that supports the use of GLP-1s for stroke prevention. We need more data, though. We need trials that focus only on patients with stroke, for example, there have been studies in patients with cardiovascular disease broadly that include stroke patients. But if you look at the subcategory just of stroke patients alone, the data in that subgroup alone don't always show a benefit. And so, we need more data that's focused on stroke patients alone. So, I think the data are continuing to emerge, but we need more still.  Dr Grouse: Is there any development in the thought about whether we should be putting patients on antiplatelet therapies for incidental, incidentally identified strokes? For instance, if you got an MRI for migraine or for other reasons and you found one, no history of any stroke-like symptoms. Should we be putting these patients on aspirin or any other types of therapies?  Dr Elkind: That's a really great question. And again, it's an area where there's some controversy and really, there's really no definitive data that would support using antiplatelet therapy in people with incidentally discovered infarcts or what we call, you know, whispering strokes or silent strokes. Many stroke neurologists will use antiplatelet agents. This is one of those areas where it's so important to identify the risk factors. As we were saying before, patients who have other neurological disorders like migraine or epilepsy may turn out to have cardiovascular risk factors like diabetes and high blood pressure. That's why it's so important for neurologists to be able to treat those patients or refer them to specialists who can. Patients who have incidentally discovered lesions similarly are a group where we should be looking for risk factors. So, I don't think of it only in terms of do we put them on an antiplatelet or not, but really more holistically, can we identify their other risk factors and address those? Should the patient's information be entered into a risk calculator like PREVENT, for example, so that we can come up with a more global or holistic measure of their cardiovascular risk and address that as appropriate? Because if they are at risk for stroke, they're also at risk for cardiac events, including heart attack, heart failure, sudden cardiac arrest, and so forth. So, I think of it as a, as a great kind of teachable moment or an opportunity to catch somebody and bring them into the healthcare system more broadly and address those other potential risk factors.  Dr Grouse: Speaking of, of risk factors that we often like to think about and work up when possible, in cases where it seems certainly possible the patient had an embolic stroke, but perhaps we've done a few weeks or four weeks of cardiac monitoring, have not found any evidence of atrial fibrillation. What's new and what's the current recommendations for doing further monitoring when there's high suspicion for cardioembolic stroke?  Dr Elkind: This is a really active area of investigation, and guidelines suggest that we should do some cardiac monitoring for atrial fibrillation after an unexplained stroke, but it's not clear how much we should do. Studies generally show that the longer you follow somebody on a cardiac monitor after stroke, the more likely you are to detect atrial fibrillation. It could be as high as thirty percent after a few years. And that's great. And if you detect atrial fibrillation, people usually end up being recommended for a blood thinner. But how extensively we should monitor remains unknown. And I think a lot of the investigation recently has been around the question of, are there other ways to get that information rather than waiting six months or a year for the person to develop atrial fibrillation?It's a little bit funny logically to think a person has a stroke today, a year later you discover atrial fibrillation on the monitor, and you say, "Oh, now I know what caused your stroke a year ago." Right? The temporality, the causality perhaps is off in that case. And so, wouldn't it be better if we could tell what somebody's risk of having another cardioembolic stroke is, or the likelihood that they have atrial fibrillation is at the time that you first see them for the stroke, you know, in the hospital, for example. And so, there's some really new technologies that have evolved like AI or artificial intelligence interpretation of EKGs that can give a really good indication of which people are gonna go on to develop atrial fibrillation. And so, I think we need some more trials in that area to demonstrate that we can detect the risk of AFib and treat that even before it appears on one of those delayed monitors. That's an area that I think is very exciting right now. There's also a further question with regard to how to treat these patients, which is that sometimes atrial fibrillation is a consequence of the stroke itself. So, we can think about what people call known AF, meaning atrial fibrillation that's known about before the stroke even occurs, versus AF that's detected after a stroke, or AF-DAS, people will say. Those may have very different implications for the risk of recurrence and what the person's cardiovascular status is. So, I think what we've learned over the last few years is that atrial fibrillation, it used to be like the slam dunk for a stroke neurologist. It was the easy thing. You know, you had a stroke, you have AFib, you should be on a blood thinner. Now we know that there's lots of different kinds of AFib. There's AFib before stroke, there's AFib after stroke, there's burden of atrial fibrillation. So, some people may have 30 seconds of AFib, some people may have several hours, some people may be in it continuously. It comes and goes, and that can make it challenging to manage. So, we have a lot more work to do to understand this problem better.  Dr Grouse: That also gets me into some other interesting areas that I think there's still some question, you know, how aggressive should you be? How often is it a case of is this correlated or is this causative? For instance, when a patent foramen ovale is, is discovered in patients with cryptogenic stroke. Are there any tools or new developments to help us understand whether these PFOs should be closed in these cases?  Dr Elkind: PFO and stroke is a great story that's been going on for decades. And again, we've made tremendous progress in the last several years. So, it's true that about 20% or so of people have a PFO, and because of that, it can be really hard to say with any certainty whether an individual patient sitting in front of you, that the PFO was the cause of their stroke. Rarely we can have a really high degree of certainty. You know, if somebody has, uh, a DVT, for example, and shortly after that maybe they have pulmonary embolism and then a stroke, and we can say, "Oh, clearly this was a paradoxical embolism," went to the lungs and then some crossed over and went to the brain. That happens really infrequently. Most of the time you're faced with a patient who has a PFO and a stroke, and they may have some other risk factors. There are some tools that we can use to help figure out the likelihood that a PFO is related to a stroke. One of those is called the ROPE score or the risk of paradoxical embolism score that was developed by David Thaler and, uh, David Kent from Tufts and a group of other investigators as well. That score allows one to say what the likelihood is that the PFO was causative of the stroke, and it's based on a person's risk factors such that the younger you are, the more likely it is the PFO caused the stroke. And the absence of risk factors make it more likely that the PFO caused the stroke. So, the higher your ROPE score indicating the fewer other reasons you have a stroke, the more likely the PFO is to be causative. So that can be helpful in identifying patients who may have had a stroke due to their PFO. There are other features that are identified in something called the PASCAL score, which is a way of assessing the degree of shunting and whether or not there's an atrial septal aneurysm that can be used as additional factors that lead to the likelihood that a PFO was causative rather than just incidental. So, by putting this kind of information together, we can kind of do precision neurology or precision prevention by identifying which patients with a PFO are really the ones we need to worry about and do procedures like closure.  Dr Grouse: I look forward to hearing more and learning more as more advances are made in these areas. Dr Elkind: Thank you.   Dr Grouse: And thank you so much for joining us today to talk about your article.   Dr Elkind: Oh, I appreciate it. Thank you for giving me the opportunity. I really enjoyed it.  Dr Grouse: Again, today I've been interviewing Dr. Mitchell Elkind about his article on stroke prevention. This article appears in the June 2026 Continuum issue on cerebrovascular disease. Be sure to check out Continuum Audio episodes from this and other issues, and thank you to our listeners for joining today.  Dr Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

In this MedAxiom HeartTalk, host Melanie Lawson, MS, sits down with Jasen Gundersen, MD, CEO and Christie Yoder, COO at CardioOne. Together, they explore practical strategies for immediate growth in cardiology practices, emphasizing small, achievable changes over long-term planning. 

In this special 500th episode of Heart Doc VIP, Dr. Joel Kahn reflects on the personal and professional journey that shaped his 36-year career in cardiology and preventive medicine. From his childhood in Detroit and medical training at the University of Michigan to founding the Kahn Center for Cardiac Longevity, Dr. Kahn shares the mentors, experiences, and lessons that influenced his approach to patient care. He also reviews new research on heart disease mortality in the United States, vitamin K2 and coronary artery calcium progression, plant-based diets for chronic kidney disease, factors influencing carotid intima-media thickness (CIMT), and emerging advances in calcium scoring technology.  Thank you to Igennus for sponsoring this milestone episode. Visit Igennus.com/DrKahn and use code DRKAHN for savings on their vegan-certified supplements.

Send us Fan MailDr. Jodi Nishida is a returning guest on our show! Be sure to check out her first appearance on episode 721 of Boundless Body Radio!Dr. Jodi Nishida is a Doctor of Pharmacy and accredited Metabolic Healthcare Practitioner who has been in healthcare for over 30 years. After experiencing the ketogenic lifestyle's effect on her own autoimmune condition, she decided to build a keto-based medical practice called The Keto Prescription so others could benefit from it too.Over the last several years, she has helped thousands of patients realize the benefits of clean, medically guided keto. With an accreditation in ketogenic nutrition; certifications in cardiovascular disease management, pharmacogenomics, and medication management; and first-hand experience working in gastrointestinal clinics and women's health clinics, Jodi works closely with each patient to tailor keto to their medications, medical conditions, lifestyle, and socioeconomic situation.Health is not a one-size-fits-all approach, and we all have unique challenges. Because all of us are addicted to sugar and processed food to some extent, fueled largely by our food industry, she has also partnered with two highly qualified psychologists locally, to help her patients address the root of their eating behaviors.She is also the owner of her latest venture, Rise Cafe, located in Honolulu, HI! The coffee shop is an offshoot of her medical practice where she can proudly bring low carb, no sugar items to the people of Hawaii. Rise Cafe is their combined effort to improve the health of those who visit!Find Dr. Jodi Nishida at-https://weloverise.com/IG- @theketoprescriptionhttps://www.theketoprescription.com/Check out the HILAROUS reviews on Yelp!Find Boundless Body at-myboundlessbody.comBook a session with us here! 

Listener feedback, transcatheter tricuspid valve replacement, a new metabolic disease called CKM, the ARISE-FLUIDS Trial, the BIHCA trial, and temporal trends in ICD therapies are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback LOSE-AF Trial https://jamanetwork.com/journals/jama/fullarticle/2849335 ARREST-AF Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2840225 POP-AF Trial https://doi.org/10.1093/eurheartj/ehaf689 PRAGUE-25 Trial https://www.jacc.org/doi/10.1016/j.jacc.2025.04.042 II Transcatheter Tricuspid Valve Replacement TRISCEND Cost Study https://doi.org/10.1016/j.shj.2026.101049 TRISCEND II Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2401918 III More Disease Creation – the CKM Syndrome ACC/AHA Release First-Ever Guideline for CKM Syndrome https://www.medscape.com/viewarticle/acc-aha-release-first-ever-guideline-ckm-syndrome-2026a1000jbs CKM Guideline in Circulation https://www.ahajournals.org/doi/10.1161/CIR.0000000000001447 IV Two Trials That Teach Important EBM Lessons ARISE-FLUIDS Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2516225 Dr Josh Farkas Post on X https://x.com/PulmCrit/status/2065064796270022845?s=20   V  Bicarbonate for Inpatient Cardiac Arrest –The BIHCA trial BIHCA Trial https://jamanetwork.com/journals/jama/fullarticle/2850405 VI The Decline of VT in Heart Failure Trends and Outcomes in ICD Recipients: 15-Year Analysis https://doi.org/10.1093/europace/euag110 Declining Risk of Sudden Death in HF https://www.nejm.org/doi/full/10.1056/NEJMoa1609758 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

The March 2026 ACC/AHA Guideline on the Management of Dyslipidemia made a major pivot regarding Lipoprotein(a) by establishing a formal recommendation for universal screening in adults. This 2026 guideline, published in the Journal of the American College of Cardiology, issued a Class 1 recommendation stating that every adult should have their Lp(a) measured at least once in their lifetime. Because Lp(a) levels are genetically determined and remain highly stable throughout a person's life, a single lifetime check is sufficient for the vast majority of the population to establish their baseline risk. Well, that's great for Family medicine or internal medicine, but how does that affect us in women's health? Well, it's complicated: lipoprotein(a) has been associated with an increased risk of VTE and has also been associated, in some studies, with FGR, preeclampsia, and preterm birth! So, can these patients receive oral contraceptives? What about Perioperative and postop care? Do these patients require anticoagulation? What about pregnancy- is LDA recommended here? And lastly, what about TXA use in patients with HMB? This podcast topic comes from one of our podcast family members who is an OBGYN military personnel caring for our wonderful troops overseas. Listen in for details!16% OFF TONA ACTIVE WEAR PROMO: https://tonaactive.com/discount/CHAPANOSPINOBG1. Ezzat, D., Lopez, D. M., Claggett, B. L., Li, L., Mohammadnia, N., Schuermans, A., Hemeryck, J., Chang, A., Murillo, S., O'Donoghue, M. L., Bikdeli, B., Yu, Z., Natarajan, P., Patel, A. P., Pabon, M. A., & Honigberg, M. C. (2026). Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men. European Heart Journal, ehag252. https://doi.org/10.1093/eurheartj/ehag2522.ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Dyslipidemia Writing Committee. (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation, 153, e1155–e1300. https://doi.org/10.1161/CIR.00000000000014233. CDC MEC 4. Prevention of Venous Thromboembolism in Gynecologic Surgery: ACOG Practice Bulletin, Number 232. Obstetrics and Gynecology. 2021. Committee on Practice Bulletins—Gynecology5. Sofi F, Marcucci R, Abbate R, Gensini GF, Prisco D.Lipoprotein(a) as a Risk Factor for Venous Thromboembolism: A Systematic Review and Meta-Analysis of the Literature.Seminars in Thrombosis and Hemostasis. 2017. Dentali F, Gessi V, Marcucci R, et al. Lipoprotein (A) and Venous Thromboembolism in Adults: The American Journal of Medicine. 2007.

This week we go back 2.5 years and delve into the world of cardiovascular surgery when we review a review of STS data on the pulmonary artery band (PAB). The STS assigns a STAT category of 4 to this operation, denoting higher risk for mortality. Is this warranted? Are all PAB candidates equal? What features are associated with higher or lower mortality rates in patients undergoing banding? Should the data in this work drive innovation to avoid the PAB in some settings? These are amongst the questions posed to the senior author of this week's work, cardiovascular surgeon Dr. Tara Karamlou who is Professor of Surgery at the Cleveland Clinic in Cleveland, Ohio. DOI: 10.1016/j.athoracsur.2023.09.020

It beats. It throws blood. It breaks – but not if Dr. Herman Taylor can help it. Cardiology is a vast field but Dr. Taylor joined for a 101 on how the heart works, and how to take care of it. Get pumped for valves, tubes, electrical shocks, heavy metal hearts, what to do in an emergency, and what your heart wants you to eat. Also: the worst heart-themed art out there.  Browse Dr. Taylor's publications on ResearchGate A donation went to the Center for Black Agency and Resilience Full-length (*not* G-rated) Cardiology episode + tons of science links More kid-friendly Smologies episodes! Become a patron of Ologies for as little as a buck a month OlogiesMerch.com has hats, shirts, hoodies, totes! Follow Ologies on Instagram and Bluesky Follow Alie Ward on Instagram and TikTok Sound editing by Mercedes Maitland of Maitland Audio Productions and Jake Chaffee Made possible by work from Noel Dilworth, Susan Hale, Kelly R. Dwyer, Aveline Malek and Erin Talbert Smologies theme song by Harold Malcolm Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Health economics is not just about reimbursement. It is about proving how a technology reduces the total cost of care. In this episode, Betty Tsai, President of Cardiology Services International, explains why medtech companies must think beyond existing CPT or MS-DRG codes when shaping their commercialization strategies. Speaking with Saul at the MedTech Innovator event, she highlights how health economics reveals the true cost of a patient journey, from initial admission through readmissions and long-term care. Betty explores how value-based care and CMS performance metrics are reshaping hospital revenue and influencing adoption decisions. She also discusses alternative reimbursement pathways, such as the New Technology Add-on Payment, and emphasizes that companies demonstrating both clinical and economic value are more attractive to providers and investors. Tune in and learn why proving economic value may be one of the most important steps in driving medtech adoption. Resources: Connect with and follow Betty Tsai on LinkedIn.

Most people use moderation as a reason to keep doing what they are doing. Dr. Columbus Batiste says that is exactly the mindset that can have lasting health implications. In this episode of NHA Today, Dr. Stephan Esser sits down with Dr. Columbus Batiste, board-certified interventional cardiologist, author, and co-founder of Healthy Heart Nation. Known as the Healthy Heart Doc, Dr. Batiste has spent his career doing what most cardiologists do not: asking patients not just what they eat, but what they eat for their health - and then building a plan around what they actually want. His personal story is the backbone of this conversation. His father was health-conscious, ran a health food store, and juiced long before it was fashionable - but also loved sodasand sweets in moderation. He died from the effects of diabetes. Reading Caldwell Esselstyn's chapter titled Moderation Kills changed the course of Dr. Batiste's career. In this conversation you will learn:• Why moderation is a justification we only apply to things we know we should not be doing• The three most heart-protective food groups and why they work at the cellular level• How to talk to patients (or yourself) about food in a way that actually creates change• The SELFISH acronym: seven pillars of heart health from spirituality to humor• Why 80% of health outcomes happen outside the doctor's office• The role of stress, presence, and relationships in cardiovascular disease• Dr. Batiste's take on AI in medicine and what an elderly patient said that stopped him cold• What he is bringing to the NHA Annual Conference this June ---ABOUT DR. COLUMBUS BATISTE---Columbus Batiste, MD is a board-certified interventional cardiologist, co-founder of Healthy Heart Nation, and author of Selfish: A Cardiologist's Guide to Curing a Stressed and Broken Heart. He is the Regional Chief of Cardiology for Southern California Permanente Medical Group and a celebrity media contributor featured in documentaries, articles, and podcasts worldwide. He will be speaking at the NHA Annual Conference, June 25 to 28, 2026. ---LINKS AND RESOURCES---Full episode and show notes: Subscribe: https://www.healthscience.org/podcast/NHA Annual Conference (June 25 to 28, 2026): https://checkout.healthscience.org/2026-nha-conferenceDr. Batiste's website: https://drbatiste.comFollow Dr. Batiste on Instagram: https://www.instagram.com/healthyheartdoc/Dr. Batiste on LinkedIn: https://www.linkedin.com/in/drbatiste/Book - Selfish: A Cardiologist's Guide: [add purchase link]Follow Dr. Esser on Instagram: https://www.instagram.com/esserhealth/

A round-up of the main headlines in Sweden on June 9th 2026. You can hear more reports on our homepage www.radiosweden.se, or in the app Sveriges Radio. Presenter/producer: Sujay Dutt.

High blood pressure is often unnoticed until serious issues arise. In this episode, we explore what causes it and how simple daily habits—like diet, exercise, sleep, stress management, and hydration—can help lower it naturally and protect your heart.  Learn more about Sudip Saha, MD 

Dr. Ami Bhatt is the Chief Innovation Officer for the American College of Cardiology and Chair of FDA's Digital Health Advisory Committee.We discuss the intersection of medicine and technology, highlighting the impact of digital health on chronic disease management, patient education, and access to care. The conversation delves into telemedicine, remote monitoring, patient empowerment, integrative care, and the future of predictive and preventative healthcare.This episode was sponsored by Ardelyx.

Chemical cardioversion in the ED, HF monitoring, weight loss in AF, and surgical LAA excision are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Chemical Cardioversion of AF in the ED: The FLECA-ED Trial FLECA-ED Rationale paper https://pmc.ncbi.nlm.nih.gov/articles/PMC10299428/ FLECA-ED ESC Slides https://esc365.escardio.org/presentation/321209 Review on Flecainide Use Despite CAST https://doi.org/10.1016/j.hrthm.2025.08.034 RACE 7 ACWAS Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1900353 II Heart Failure Monitoring – The ALLEVIATE-HF Trial ALLEVIATE-HF Trial https://doi.org/10.1016/j.jacc.2026.03.075 CHAMPION Trial https://doi.org/10.1016/S0140-6736(11)60101-3 GUIDE HF Trial https://doi.org/10.1016/S0140-6736(21)01754-2 ALLEVIATE-HF Editorial: Alerts Are Not Treatment https://doi.org/10.1016/j.jacc.2026.04.014 Steve Stiles Medscape report on CHAMPION https://www.medscape.com/viewarticle/755189 III A Negative Weight Loss Study in AF LOSE-AF Trial https://jamanetwork.com/journals/jama/fullarticle/2849335 IV Surgical LAA Excision OPINION Trial https://doi.org/10.1093/eurheartj/ehaf674 LAAOS 3 trial https://www.nejm.org/doi/full/10.1056/NEJMoa2101897 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we speak with 2 pioneers in the field of pediatric cardiac critical care, Dr. Anthony Rossi and Dr. Gil Wernovsky. Both were present at the very start of the field of cardiac critical care for children. What was it like in an era before transesophageal echocardiography or even postoperative echo? Why was the advent of the bidirectional cavo-pulmonary anastomosis such a game changer in the care of children with heart disease? What do Drs. Rossi and Wernovsky think were the most important improvements to care for children with heart disease in their 35+ year careers? What about care today troubles these intensive care gurus? This is a rare opportunity to speak with two who have seen and done it all in cardiac critical care for children.For those interested to hear Dr. Rossi speak about goal directed therapy, take a listen to episode 21 and episode 200 of this podcast!

The following question refers to Section 7.1 of the 2025 ACS Guidelines. The question is asked by Thomas Jefferson medical student and CardioNerds Academy Intern Dr. Grace Qiu, answered first by University of Michigan fellow and CardioNerds FIT Ambassador Dr. Kayla Secrest, and then by expert faculty Dr. Sunil Rao. Dr. Rao is an interventional cardiologist, Professor of Medicine at NYU Grossman School of Medicine, Deputy Director of the Leon H. Charney Division of Cardiology, and the Director of Interventional Cardiology for the NYU Langone Health System. He is the Editor-in-Chief for Circulation Cardiovascular Interventions and was the Chair of the Writing Committee for the 2025 ACS Guidelines. This episode is part of our comprehensive Decipher the Guidelines Series covering the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Question #1 A 68-year-old man with a history of hypertension, hyperlipidemia, stage III chronic kidney disease, and prior tobacco use presents to a local emergency department with reports of chest pain while raking leaves at home. Upon arrival, he is hemodynamically stable with a heart rate of 86 beats per minute and a blood pressure of 133/85 mmHg. His EKG reveals ST elevations in the septal and anterior leads (V1-V4). He is given 324mg of aspirin and is promptly evaluated by the interventional cardiology team, who elects to take him emergently to the catheterization lab. Upon arrival to the catheterization lab, the nurse asks the interventional fellow which access sites they should prep for this case? How should the interventional fellow respond? A Right radial artery only B Radial + bilateral femoral C Bilateral femoral only Answer #1 Explanation  The correct answer is B. Radial and bilateral femoral Radial artery access is the preferred vascular access site for coronary angiography and PCI in patients with ACS. Transradial access has been shown to reduce mortality, bleeding, and vascular complications compared with transfemoral access (Class I, LOE A). Radial access also allows earlier ambulation and is associated with greater patient comfort. Although the right radial artery is the most widely studied upper-extremity access site, alternative sites such as the ulnar and distal radial arteries have demonstrated similar outcomes. However, the radial artery may be required as a bypass conduit for CABG. In institutions where the radial artery is routinely used for surgical grafting, this potential future use should be considered when selecting vascular access. In addition, transfemoral access—preferably performed with ultrasound guidance—should be considered in patients in whom temporary mechanical circulatory support (MCS) is anticipated or in those for whom radial access is not feasible due to anatomical or technical constraints. Prepping bilateral groins in addition to the radial artery provides a backup strategy for urgent MCS placement or for transition to femoral access should radial access fail. For these reasons, prepping both the radial artery and bilateral groins is the most appropriate response. Radial-only preparation is incorrect because, although radial access is preferred, patients with STEMI may still require emergent MCS or alternative access if the radial artery is unsuitable. Preparing only the wrist without backup femoral access may delay care should hemodynamic instability occur. Femoral-only preparation is incorrect because transradial access provides superior outcomes in ACS, including significant reductions in all-cause mortality, major bleeding, and vascular complications. RCTs and meta-analyses, including MATRIX (which showed lower MACE and net adverse clinical events with radial access) and SAFARI-STEMI (which showed no difference in mortality but was underpowered)—support radial as first-line access when feasible. Main Takeaway For patients with ACS undergoing PCI, radial access is strongly preferred to reduce mortality, bleeding, and vascular complications. Guideline Loc. Section 7.1  

A life-long treatment for high LDL, a VESALIUS subanalysis, tirzepatide beats semaglutide again, arrhythmia burden in cardiac amyloidosis, and a lipid guideline rebuttal are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Permanent Lipid Lowering therapy Verve 102 Therapy for FH https://www.nejm.org/doi/full/10.1056/NEJMoa2601283 II Vesalius Substudy on PCSK9i Use in Patients With Previous PCI VESALIUS Subgroup Analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.080616 VESALIUS Study - NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2514428 III Tirzepatide looking to be best again SURPASS-EARLY Trial https://www.acpjournals.org/doi/10.7326/ANNALS-25-05602 SURMOUNT-5 Trial https://www.nejm.org/doi/abs/10.1056/NEJMoa2416394 IV Arrhythmias in Cardiac Amyloidosis Loop Recorders Reveal Arrhythmias in Cardiac Amyloidosis https://www.medscape.com/viewarticle/loop-recorders-reveal-arrhythmias-cardiac-amyloidosis-2026a1000gq9 EXCALIBUR Study https://www.jacc.org/doi/10.1016/j.jacc.2026.04.030 V Lipid Guidelines ·       In Defense of the 2026 Dyslipidemia Guideline https://www.medscape.com/viewarticle/defense-2026-dyslipidemia-guideline-2026a1000hd0 Lipid Guidelines: Four Major Concerns https://www.medscape.com/viewarticle/lipid-guidelines-four-major-concerns-2026a1000fim You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

CardioNerds Dr. Joseph Kassab, Dr. Mariana Garcia-Arango, and Dr. Christopher Mason explore the technological revolution of Coronary CT Angiography (CCTA) with expert faculty Dr. Michael Gallagher. The discussion details how CCTA has evolved into a frontline diagnostic and preventive tool, moving beyond simple anatomy to incorporate physiology via CT-FFR and biology through AI-driven plaque quantification. The episode reviews landmark evidence like the SCOT-HEART and PROMISE trials, the nuances of CAD-RADS 2.0 reporting, and the emerging role of AI in monitoring treatment response and personalizing cardiovascular care. Critically, they also discuss some of the assumptions and limitations of these techniques. Stay tuned for a matching review article to be submitted to US Cardiology Review, the official Journal of CardioNerds. This episode was supported by an independent medical education grant from HeartFlow. All CardioNerds education is planned, produced, and reviewed solely by CardioNerds.  Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here. CardioNerds Multimodality Cardiovascular Imaging PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll Pearls Shift in Paradigm: CCTA is no longer just an anatomic test; with some key limitations, it can provide anatomy, physiology (CT-FFR), and plaque biology (AI-CPA) in a single non-invasive scan. The “Power of Zero” vs. Plaque: While a normal CCTA has a >95% negative predictive value, future MIs often arise from non-obstructive plaque that traditional stress tests might miss. CAD-RADS 2.0 Utility: The addition of plaque burden modifiers (P1–P4) is a “game changer,” allowing clinicians to identify high-risk patients who need aggressive lipid-lowering despite having only mild stenosis. CT-FFR as a Virtual Stress Test: CT-FFR uses computational fluid dynamics to simulate blood flow, potentially reducing unnecessary invasive catheterizations by approximately 61% without sacrificing safety. Seeing the Invisible: AI-based quantitative plaque analysis (QCPA) can identify “subvisual” plaque and low-attenuation (lipid-rich) components that are the primary drivers of acute coronary syndromes. Show Notes How has the role of CCTA changed compared to traditional functional testing? Historically, stress testing answered “is there ischemia today?”, which often reflects late-stage disease. CCTA identifies disease across the entire spectrum, asking “is there atherosclerosis and how much plaque is present?”. Landmark evidence: SCOT-HEART showed a 41% relative risk reduction in MI at 5 years attributed to intensified preventive therapies, and PROMISE showed CCTA was better at selecting patients who truly needed invasive angiography. Diagnostic CCTA imaging depends on the protocol, contrast timing, heart rate, heart rhythm, breathholding, scanner quality, and several patient factors (obesity, prior stents, heavy calcification, complex bypass anatomy, and motion artifact all may limit imaging). “CCTA is exceptional for the right patient, with the right scanner, and the right team.” What are the key modifiers introduced in CAD-RADS 2.0, and why do they matter? CAD-RADS 2.0 moved beyond stenosis severity to include plaque burden (P0 to P4), high-risk plaque (HRP) features, and the presence of ischemia based on CT-FFR. It serves as a clinical decision support tool: a patient with mild (25-49%) stenosis but “extensive” (P4) plaque burden is considered high risk and warrants aggressive risk factor modification. How is CT-FFR calculated, and when is it most useful in clinical practice? CT-FFR uses resting CCTA data and computational fluid dynamics to create a 3D model of coronary flow during simulated maximal hyperemia. It is often used for intermediate lesions (40–90% stenosis) to predict if they are  ischemia-producing, guiding the decision whether to proceed with invasive angiography.  The assumptions necessary for this computational modeling may not apply well to patients with microvascular dysfunction, significant myocardial scar or prior infarction, or ventricular hypertrophy. Still, data indicate that CT-FFR performs similarly to PET in predicting hemodynamically significant lesions.  CT-FFR performs well at the extremes (either clearly normal or clearly abnormal). Accuracy dips, however, in the intermediate range (~0.75-0.80), where decision-making is most critical. In this grey zone, additional factors can help guide the approach, including the amount of myocardium supplied, translesional gradient, and plaque features.   CT-FFR has not been validated in distal segments, stented segments, heavily calcified coronary arteries, or in patients with severe aortic stenosis. Caution with CT-FFR should be utilized in very calcified coronary segments.  What is AI-based quantitative plaque analysis (QCPA), and what metrics are ready for clinical use? This is potentially a paradigm shift, moving away from stenosis-centric thinking to a more disease burden and plaque biology focus. QCPA uses deep learning algorithms to automatically segment the vessel wall and quantify plaque volume in mm³. Ready for “prime time” metrics include: Total Plaque Volume (TPV), non-calcified plaque volume, and Low-Attenuation Plaque (LAP) burden. Can serial CCTA be used to monitor the effectiveness of medical therapies like statins? While not yet a routine guideline-driven practice, trials like PARADIGM and EVAPORATE show that therapies can stabilize plaque; notably, CCTA is better for monitoring than CAC scores, which can be misleading as statins often increase plaque calcification as part of the stabilization process. There are no randomized trials that serial CCTAs improve outcomes. Cost and radiation exposure will be notable limitations. Serial scan timing, scan acquisition and interpretation standardization would be key. Dr. Gallagher notes that we are moving toward a world in which plaque burden may become a “treatment biomarker,” similar to tumor burden in oncology.  References 1. Coronary Computed Tomography Angiography From Clinical Uses to Emerging Technologies: JACC State-of-the-Art Review. Abdelrahman KM, Chen MY, Dey AK, et al. Journal of the American College of Cardiology. 2020;76(10):1226-1243. doi:10.1016/j.jacc.2020.06.076. 2. Non-Invasive Imaging in Coronary Syndromes: Recommendations of the European Association of Cardiovascular Imaging and the American Society of Echocardiography, in Collaboration With the American Society of Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Edvardsen T, Asch FM, Davidson B, et al. Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography. 2022;35(4):329-354. doi:10.1016/j.echo.2021.12.012. 3. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Gulati M, Levy PD, Mukherjee D, et al. Journal of the American College of Cardiology. 2021;78(22):e187-e285. doi:10.1016/j.jacc.2021.07.053. 4. Contemporary, Non-Invasive Imaging Diagnosis of Chronic Coronary Artery Disease. van der Bijl P, Gulati M, Saraste A, et al. Lancet (London, England). 2025;406(10519):2577-2587. doi:10.1016/S0140-6736(25)01586-7. 5. State of the Art: Evaluation and Medical Management of Nonobstructive Coronary Artery Disease in Patients With Chest Pain: A Scientific Statement From the American Heart Association. Slipczuk L, Blankstein R, Bucciarelli-Ducci C, et al. Circulation. 2025;152(23):e443-e466. doi:10.1161/CIR.0000000000001394. 6. Diagnostic Performance of Fractional Flow Reserve Derived From Coronary CT Angiography: The ACCURATE-CT Study. Li C, Hu Y, Jiang J, et al. JACC. Cardiovascular Interventions. 2024;17(17):1980-1992. doi:10.1016/j.jcin.2024.06.027. 7. Clinical Outcomes Based on Coronary Computed Tomography-Derived Fractional Flow Reserve and Plaque Characterization. Sato Y, Motoyama S, Miyajima K, et al. JACC. Cardiovascular Imaging. 2024;17(3):284-297. doi:10.1016/j.jcmg.2023.07.013. 8. Clinical Use of Coronary Computed Tomography Angiography-Derived Fractional Flow Reserve: Expert Consensus by an International Working Group. Tang CX, Leipsic JA, Nørgaard BL, et al. European Radiology. 2026;:10.1007/s00330-025-12313-6. doi:10.1007/s00330-025-12313-6. 9. Diagnostic accuracy of computed tomography–derived fractional flow reserve: a systematic review. Cook CM, Petraco R, Shun-Shin MJ, et al. JAMA Cardiol. 2017;2(7):803-810. Doi:10.1001/jamacardio.2017.1314 10. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). Nørgaard BL, Leipsic J, Gaur S, et al. J Am Coll Cardiol. 2014;63(12):1145-1155. Doi:10.1016/j.jacc.2013.11.043 11. Comparison of coronary computed tomography angiography, fractional flow reserve, and perfusion imaging for ischemia diagnosis. Driessen RS, Danad I, Stuijfzand WJ, et al. J Am Coll Cardiol. 2019;73(2):161-173. Doi:10.1016/j.jacc.2018.10.056. 12. 1-year outcomes of FFRCT-guided care in patients with suspected coronary disease: the PLATFORM study. Douglas PS, De Bruyne B, Pontone G, et al. J Am Coll Cardiol. 2016;68(5):435-445. Doi:10.1016/j.jacc.2016.05.057. 13. Comparison of an initial risk-based testing strategy vs usual testing in stable symptomatic patients with suspected coronary artery disease: the PRECISE randomized clinical trial. Douglas PS, Nanna MG, Kelsey MD, et al; PRECISE Investigators. JAMA Cardiol. 2023;8(10):904-914. Doi:10.1001/jamacardio.2023.2595. 14. Diagnostic and clinical value of FFRCT in stable chest pain patients with extensive coronary calcification: the FACC study. Mickley H, Veien KT, Gerke O, et al. JACC Cardiovasc Imaging. 2022;15(6):1046-1058. doi:10.1016/j.jcmg.2021.12.010. 15. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results From the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART). Williams MC, Kwiecinski J, Doris M, et al. Circulation. 2020;141(18):1452-1462. doi:10.1161/CIRCULATIONAHA.119.044720. 16. AI-Guided Quantitative Plaque Staging Predicts Long-Term Cardiovascular Outcomes in Patients at Risk for Atherosclerotic CVD. Nurmohamed NS, Bom MJ, Jukema RA, et al. JACC. Cardiovascular Imaging. 2024;17(3):269-280. doi:10.1016/j.jcmg.2023.05.020. 17. Interaction of AI-Enabled Quantitative Coronary Plaque Volumes on Coronary CT Angiography, FFRCT, and Clinical Outcomes: A Retrospective Analysis of the ADVANCE Registry. Dundas J, Leipsic J, Fairbairn T, et al. Circulation. Cardiovascular Imaging. 2024;17(3):e016143. doi:10.1161/CIRCIMAGING.123.016143. 18. Prognostic Value of AI-Based Quantitative Coronary CTA vs Human Reader-Based Visual Assessment: Results From the CONFIRM2 Registry. van Rosendael A, Nakanishi R, Bax JJ, et al. JACC. Cardiovascular Imaging. 2026;19(3):345-359. doi:10.1016/j.jcmg.2025.09.021.13. Pericoronary Adipose Tissue as a Marker of Cardiovascular Risk: JACC Review Topic of the Week. Tan N, Dey D, Marwick TH, Nerlekar N. Journal of the American College of Cardiology. 2023;81(9):913-923. doi:10.1016/j.jacc.2022.12.021. 19. Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy: Final Results of the EVAPORATE Trial. Budoff MJ, Bhatt DL, Kinninger A, et al. European Heart Journal. 2020;41(40):3925-3932. doi:10.1093/eurheartj/ehaa652. 20. Coronary CT Angiography Evaluation With Artificial Intelligence for Individualized Medical Treatment of Atherosclerosis: A Consensus Statement From the QCI Study Group. Schulze K, Stantien AM, Williams MC, et al. Nature Reviews. Cardiology. 2026;23(2):100-115. doi:10.1038/s41569-025-01191-6.

Three more digoxin trials, yet another GLP-1 drug on the horizon, vagal nerve stimulation, trial inside baseball, and more on lipid guidelines are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I More About Low-dose Digoxin in HF — The DECISION Trial(s) DECISION Trial https://www.nature.com/articles/s41591-026-04406-6 Digitalis Glycosides in HF — JAMA Meta-Analysis https://jamanetwork.com/journals/jama/fullarticle/2848972 DIGIT-HF Trial https://www.nejm.org/doi/10.1056/NEJMoa2415471 RADIANCE Trial (1993) https://www.nejm.org/doi/full/10.1056/NEJM199307013290101 DECISION Withdrawal Study https://doi.org/10.1093/eurheartj/ehag385 Digoxin Discontinuation vs Continuation in Chronic HF https://doi.org/10.1016/j.amjcard.2007.02.099 II Yet another GLP-1 Drug Announced this Week Lillly News Release on Retatrutide https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss III A Big Story in HF Science – Vagal Nerve Stimulation in HFrEF ANTHEM HFrEF trial https://doi.org/10.1016/j.jacc.2026.03.040 Editorials An Unfinished ANTHEM https://doi.org/10.1016/j.jacc.2026.04.033 When Trials Stop Prematurely https://doi.org/10.1016/j.jacc.2026.03.039 IV Lipid Guideline News Lipid Guidelines: Four Major Concerns https://www.medscape.com/viewarticle/lipid-guidelines-four-major-concerns-2026a1000fim Editorial: Time to Move Beyond the Statin Nocebo Effect  https://www.jacc.org/doi/10.1016/j.jacc.2026.04.002 Correspondence: SAMSON N-of-1 Trial of Statin, Placebo, or No Treatment https://www.nejm.org/doi/full/10.1056/NEJMc2031173 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net